Clinical trials located in

Saint-Denis

Saint-Denis city is located in France. Currently, 5 clinical trials are being conducted in this city.

Saint-Denis, located in the northern suburbs of Paris, France, is renowned for its rich history and cultural heritage. The city is home to the Basilica of Saint-Denis, a masterpiece of Gothic architecture and the burial site of French kings. Saint-Denis also played a pivotal role in the industrial revolution in France and has a diverse community, reflecting a vibrant mix of cultures. The Stade de France, the country’s national stadium, is another highlight, hosting major sporting events and concerts. This blend of historical significance and modern vibrancy makes Saint-Denis a unique urban tapestry.

  • CT-EU-00112464

    Testing setmelanotide for weight loss in genetic obesity

    This study is a research project looking into the effectiveness of a medication called setmelanotide for people who are dealing with obesity due to specific genetic variations. This medication is given under the skin. The study is designed to see if setmelanotide can help people lose weight compared to a placebo, which don’t contain any active medication.

    The study focuses on individuals who have one of several gene variants in the Melanocortin-4 Receptor pathway. These variants include changes in the POMC or PCSK1 genes, the LEPR gene, the SRC1 gene, or the SH2B1 gene. Depending on which gene variant a participant has, they will be placed into one of four sub-studies.

    The main goal of this clinical trial is to measure how much weight participants lose while taking setmelanotide over a period of 52 weeks. This will be compared to the weight loss of participants who receive the placebo. The study is carefully controlled and blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo until the study is completed.

    This trial is an important step in understanding how setmelanotide can help people with obesity linked to specific genetic factors, offering hope for a targeted treatment option.

    • Setmelanotide
    • Placebo
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.